Kanada - angličtina - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

Kanada - angličtina - Health Canada

pharmascience inc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 2mg; 0.5mg - buprenorphine (buprenorphine hydrochloride) 2mg; naloxone (naloxone hydrochloride dihydrate) 0.5mg - opiate partial agonists

Kanada - angličtina - Health Canada

pharmascience inc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - naloxone hydrochloride dihydrate, quantity: 10.9 mg (equivalent: naloxone hydrochloride?, qty 10 mg); oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: magnesium stearate; povidone; macrogol 3350; stearyl alcohol; titanium dioxide; lactose monohydrate; purified talc; polyvinyl alcohol; iron oxide red; ethylcellulose - mpl-oxycodone/naloxone modified release tablets are indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and ,- requires daily, continuous, long term treatment.,mpl-oxycodone/naloxone modified release tablets are not indicated for use in chronic noncancer pain other than in exceptional circumstances.,mpl-oxycodone/naloxone modified release tablets are not indicated as an as-needed (prn) analgesia.,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,mpl-oxycodone/naloxone is indicated as second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Kanada - angličtina - Health Canada

sandoz canada incorporated - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

Kanada - angličtina - Health Canada

hikma canada limited - naloxone hydrochloride - solution - 0.4mg - naloxone hydrochloride 0.4mg - opiate antagonists

Kanada - angličtina - Health Canada

strides pharma canada inc - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

Izrael - angličtina - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - naloxone hydrochloride (as dihydrate) 20 mg; oxycodone hydrochloride 40 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

Malta - angličtina - Medicines Authority

mercury pharma international limited 4045 kingswood road, city west business park, co, dublin, ireland - naloxone hydrochloride - solution for injection - naloxone hydrochloride 400 µg/ml - all other therapeutic products

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

max health limited - naloxone hydrochloride dihydrate 0.44 mg/ml equivalent to 0.40 mg naloxone hydrochloride - solution for injection - 400 mcg/ml - active: naloxone hydrochloride dihydrate 0.44 mg/ml equivalent to 0.40 mg naloxone hydrochloride excipient: hydrochloric acid sodium chloride water for injection - naloxone hydrochloride injection is indicated for the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic antagonist analgesics: nalbuphine, pentazocine and butorphanol. naloxone hydrochloride is also indicated for the diagnosis of suspected acute opioid overdosage.